{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T04:58:05Z","timestamp":1781153885915,"version":"3.54.1"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["1U01DA063078"],"award-info":[{"award-number":["1U01DA063078"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The prevalence of methamphetamine use disorder has risen across the United States and many other countries, which has led to a concomitant rise in methamphetamine-induced psychosis (MIP). A promising and novel approach to address MIP can be found in \u2018chill packs\u2019, a psychiatric harm reduction intervention for people using methamphetamine. Chill packs consist of several low-dose olanzapine tablets (an antipsychotic medication) that can be self-administered in the event of methamphetamine-induced insomnia, anxiety, paranoia, delusions, or other dysphoric symptoms. One recent study assessed the effectiveness of an implementation of chill packs by the San Francisco Department of Health and found that repeat psychiatric emergency visits dropped by 32% after two-months and 13% after six-months from receipt of a chill pack. While these findings are promising, more research is needed to evaluate the efficacy and generalizability of this intervention. Here we provide a narrative review which synthesizes indirect evidence and contextual information relevant to this intervention, including: the epidemiology of MIP, clinical data supporting the use of olanzapine versus other antipsychotics for MIP, evidence for as-needed outpatient antipsychotic use, as well as qualitative and other data describing the potential for misuse of olanzapine and other antipsychotics. Overall, the literature supports that the prevalence of MIP is rising sharply, causing increased psychiatric burden. This is also linked to overdose risk among patients that use illicit fentanyl or other sedatives to \u201ccome down\u201d after periods of heavy methamphetamine use. Olanzapine has demonstrated comparable efficacy for treating MIP compared to other antipsychotics with enhanced short-term sedative effects, despite a higher burden of long-term metabolic side effects. Olanzapine has very little documented misuse risk, although other agents in its class, especially quetiapine, have higher street value. Qualitative research highlights that some groups already self-administer olanzapine as a \u2018trip killer\u2019 to manage distressing psychiatric side effects from illicit drug use. Overall, we find substantial contextual evidence supporting further trials to evaluate chill packs as a harm-reduction intervention for MIP and provide recommendations for research needed to fill gaps in the evidence for this promising emerging intervention.<\/jats:p>","DOI":"10.1186\/s12954-026-01475-1","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T15:15:07Z","timestamp":1780586107000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["\u201cChill packs\u201d self-administered olanzapine as psychiatric harm reduction for methamphetamine-induced psychosis: a narrative review of the existing evidence base"],"prefix":"10.1186","volume":"23","author":[{"given":"Isabelle","family":"Ruedisueli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Marienfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casey","family":"Tiefenthaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Harvey-Vera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffanie","family":"Strathdee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph R.","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"1475_CR1","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1111\/add.16318","volume":"118","author":"J Friedman","year":"2023","unstructured":"Friedman J, Shover CL. Charting the fourth wave: geographic, temporal, race\/ethnicity and demographic trends in polysubstance fentanyl overdose deaths in the United States, 2010\u20132021. Addiction. 2023;118:2477\u201385. https:\/\/doi.org\/10.1111\/add.16318.","journal-title":"Addiction"},{"key":"1475_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2024.111409","volume":"262","author":"SL Calcaterra","year":"2024","unstructured":"Calcaterra SL, Yamkovoy K, Swathi PA, Ciccarone D, del Pozo B, Englander H, et al. U.S. trends in methamphetamine-involved psychiatric hospitalizations in the United States, 2015\u20132019. Drug Alcohol Depend. 2024;262:111409. https:\/\/doi.org\/10.1016\/j.drugalcdep.2024.111409.","journal-title":"Drug Alcohol Depend"},{"key":"1475_CR3","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1097\/yco.0000000000000717","volume":"34","author":"D Ciccarone","year":"2021","unstructured":"Ciccarone D. The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis. Curr Opin Psychiatry. 2021;34:344\u201350. https:\/\/doi.org\/10.1097\/yco.0000000000000717.","journal-title":"Curr Opin Psychiatry"},{"key":"1475_CR4","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s40263-014-0209-8","volume":"28","author":"S Glasner-Edwards","year":"2014","unstructured":"Glasner-Edwards S, Mooney LJ. Methamphetamine psychosis: epidemiology and management. CNS Drugs. 2014;28:1115\u201326. https:\/\/doi.org\/10.1007\/s40263-014-0209-8.","journal-title":"CNS Drugs"},{"key":"1475_CR5","doi-asserted-by":"publisher","DOI":"10.59158\/001c.71114","author":"G Dadhe","year":"2019","unstructured":"Dadhe G, Bettman C. The Lived Experiences of Adult Crystal Methamphetamine Users: A Qualitative Study. Psychother Counselling J Australia. 2019. . https:\/\/doi.org\/10.59158\/001c.71114","journal-title":"Psychother Counselling J Australia"},{"key":"1475_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-022-00588-7","author":"RW Harding","year":"2022","unstructured":"Harding RW, Wagner KT, Fiuty P, Smith KP, Page K, Wagner KD. \u201cIt\u2019s called overamping\u201d: experiences of overdose among people who use methamphetamine. Harm Reduct J. 2022. https:\/\/doi.org\/10.1186\/s12954-022-00588-7.","journal-title":"Harm Reduct J"},{"key":"1475_CR7","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/anoc.12012","volume":"24","author":"SA McKenna","year":"2013","unstructured":"McKenna SA. \u201cWe\u2019re supposed to be asleep?\u201d Vigilance, paranoia, and the alert methamphetamine user. Anthropol Conscious. 2013;24:172\u201390. https:\/\/doi.org\/10.1111\/anoc.12012.","journal-title":"Anthropol Conscious"},{"key":"1475_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103678","volume":"104","author":"J Friedman","year":"2022","unstructured":"Friedman J, Bourgois P, Godvin M, Chavez A, Pacheco L, Segovia LA, et al. The introduction of fentanyl on the US\u2013Mexico border: an ethnographic account triangulated with drug checking data from Tijuana. Int J Drug Policy. 2022;104:103678. https:\/\/doi.org\/10.1016\/j.drugpo.2022.103678.","journal-title":"Int J Drug Policy"},{"key":"1475_CR9","doi-asserted-by":"publisher","first-page":"388","DOI":"10.3109\/14659891.2013.810309","volume":"19","author":"WJ Cuba\u0142a","year":"2013","unstructured":"Cuba\u0142a WJ, Springer J. Quetiapine abuse and dependence in psychiatric patients: a systematic review of 25 case reports in the literature. J Subst Use. 2013;19:388\u201393. https:\/\/doi.org\/10.3109\/14659891.2013.810309.","journal-title":"J Subst Use"},{"key":"1475_CR10","doi-asserted-by":"publisher","first-page":"12","DOI":"10.4103\/2279-042x.200987","volume":"6","author":"S Kim","year":"2017","unstructured":"Kim S, Lee G, Kim E, Jung H, Chang J. Quetiapine misuse and abuse: is it an atypical paradigm of drug seeking behavior? J Res Pharm Pract. 2017;6:12\u20135. https:\/\/doi.org\/10.4103\/2279-042x.200987.","journal-title":"J Res Pharm Pract"},{"key":"1475_CR11","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1111\/add.14706","volume":"114","author":"E Stockings","year":"2019","unstructured":"Stockings E, Tran LT, Santo T, Peacock A, Larney S, Santomauro D, et al. Mortality among people with regular or problematic use of amphetamines: a systematic review and meta-analysis. Addiction. 2019;114:1738\u201350. https:\/\/doi.org\/10.1111\/add.14706.","journal-title":"Addiction"},{"key":"1475_CR12","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/S0140-6736(19)32230-5","volume":"394","author":"M Farrell","year":"2019","unstructured":"Farrell M, Martin NK, Stockings E, B\u00f3rquez A, Cepeda JA, Degenhardt L, et al. Responding to global stimulant use: challenges and opportunities. Lancet. 2019;394:1652\u201367. https:\/\/doi.org\/10.1016\/S0140-6736(19)32230-5.","journal-title":"Lancet"},{"key":"1475_CR13","doi-asserted-by":"publisher","first-page":"209033","DOI":"10.1016\/j.josat.2023.209033","volume":"151","author":"MF Zito","year":"2023","unstructured":"Zito MF, Fei Z, Zhu Y, Clingan SE, Marder SR, Mooney LJ. Psychosis among individuals with methamphetamine use disorder is associated with elevated rates of hospitalizations and emergency department visits across an academic health care system. J Subst Use Addict Treat Elsevier BV. 2023;151:209033. https:\/\/doi.org\/10.1016\/j.josat.2023.209033.","journal-title":"J Subst Use Addict Treat Elsevier BV"},{"key":"1475_CR14","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s40263-014-0209-8","volume":"28","author":"S Glasner-Edwards","year":"2014","unstructured":"Glasner-Edwards S, Mooney LJ. Methamphetamine Psychosis: Epidemiology and Management. CNS Drugs. 2014;28:1115\u201326. https:\/\/doi.org\/10.1007\/s40263-014-0209-8.","journal-title":"CNS Drugs"},{"key":"1475_CR15","doi-asserted-by":"publisher","first-page":"104480","DOI":"10.1016\/j.drugpo.2024.104480","volume":"129","author":"PO Coffin","year":"2024","unstructured":"Coffin PO, Chang Y-SG, McDaniel M, Leary M, Pating D, McMahan VM, et al. Evaluation of methamphetamine assist packs: As-needed antipsychotics for self-management of methamphetamine-associated psychiatric toxicity. Int J Drug Policy Elsevier BV. 2024;129:104480. https:\/\/doi.org\/10.1016\/j.drugpo.2024.104480.","journal-title":"Int J Drug Policy Elsevier BV"},{"key":"1475_CR16","doi-asserted-by":"publisher","first-page":"414","DOI":"10.4300\/JGME-D-22-00480.1","volume":"14","author":"J Sukhera","year":"2022","unstructured":"Sukhera J, Narrative Reviews. Flexible, Rigorous, and Practical. Journal of Graduate Medical Education. Accredit Council Graduate Med Educ. 2022;14:414\u20137. https:\/\/doi.org\/10.4300\/JGME-D-22-00480.1.","journal-title":"Accredit Council Graduate Med Educ"},{"key":"1475_CR17","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1179\/2047480615Z.000000000329","volume":"24","author":"R Ferrari","year":"2015","unstructured":"Ferrari R. Writing narrative style literature reviews. Med Writ Taylor Francis. 2015;24:230\u20135. https:\/\/doi.org\/10.1179\/2047480615Z.000000000329.","journal-title":"Med Writ Taylor Francis"},{"key":"1475_CR18","doi-asserted-by":"publisher","first-page":"100298","DOI":"10.1016\/j.ijnsa.2025.100298","volume":"8","author":"BM Jennings","year":"2025","unstructured":"Jennings BM, Yeager KA. Re-viewing the concept of saturation in qualitative research. Int J Nurs Stud Adv. 2025;8:100298. https:\/\/doi.org\/10.1016\/j.ijnsa.2025.100298.","journal-title":"Int J Nurs Stud Adv"},{"key":"1475_CR19","volume-title":"World Drug Report 2025 (Set of 3 Booklets)","author":"Crime UNO on D and","year":"2025","unstructured":"Crime UNO on D and. World Drug Report 2025 (Set of 3 Booklets). 1st ed. Bloomfield: United Nations Research Institute for Social Development; 2025.","edition":"1st ed"},{"key":"1475_CR20","unstructured":"Key Substance Use and Mental Health Indicators in the United States. Results from the 2024 National Survey on Drug Use and Health [Internet]. Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration; 2025 [cited 2025 Sept 5]. https:\/\/www.samhsa.gov\/data\/data-we-collect\/nsduh-national-surveydrug-use-and-health\/national-releases. Accessed 5 Sept 2025."},{"key":"1475_CR21","doi-asserted-by":"publisher","DOI":"10.1101\/2025.10.24.25338732","author":"JR Friedman","year":"2025","unstructured":"Friedman JR, Palamar JJ, Ciccarone D, Gaines TL, Borquez A, Shover CL, et al. Characterizing Declines in US Overdose Deaths Compared to Exponential Predictions. medRxiv. 2025. https:\/\/doi.org\/10.1101\/2025.10.24.25338732. 2025.10.24.25338732.","journal-title":"medRxiv"},{"issue":"5","key":"1475_CR22","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1001\/jamapsychiatry.2020.4321","volume":"78","author":"B Han","year":"2021","unstructured":"Han B, Cotto J, Etz K, Einstein EB, Compton WM, Volkow ND. Methamphetamine overdose deaths in the US by sex and race and ethnicity. JAMA Psychiatry. 2021;78:564. https:\/\/doi.org\/10.1001\/jamapsychiatry.2020.4321.","journal-title":"JAMA Psychiatry"},{"key":"1475_CR23","unstructured":"Drug Abuse Warning Network. National Estimates From Drug-Related Emergency Department Visits, 2024 [Internet]. Substance Abuse and Mental Health Services Administration; 2024. https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/reports\/rpt56252\/dawn-national-estimates-2024.pdf"},{"key":"1475_CR24","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1111\/acem.14094","volume":"27","author":"CE Murphy","year":"2020","unstructured":"Murphy CE, Wang RC, Coralic Z, Lai AR, Raven M. Association between methamphetamine use and psychiatric hospitalization, chemical restraint, and emergency department length of stay. Acad Emerg Med. 2020;27:1116\u201325. https:\/\/doi.org\/10.1111\/acem.14094.","journal-title":"Acad Emerg Med"},{"key":"1475_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12873-024-01163-y","author":"G Devia Jaramillo","year":"2025","unstructured":"Devia Jaramillo G, Esmeral Zuluaga N, Velandia Avellaneda VA. Effective strategies for reducing patient length of stay in the emergency department: a systematic review and meta-analysis. BMC Emerg Med. 2025. https:\/\/doi.org\/10.1186\/s12873-024-01163-y.","journal-title":"BMC Emerg Med"},{"key":"1475_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.abrep.2024.100553","volume":"19","author":"A \u00c5hman","year":"2024","unstructured":"\u00c5hman A, Karlsson A, Berge J, H\u00e5kansson A. Mortality, morbidity, and predictors of death among amphetamine-type stimulant users\u2009\u2212\u2009a longitudinal, nationwide register study. Addict Behav Rep. 2024;19:100553. https:\/\/doi.org\/10.1016\/j.abrep.2024.100553.","journal-title":"Addict Behav Rep"},{"key":"1475_CR27","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3182870310","author":"AW Jones","year":"2013","unstructured":"Jones AW, Holmgren A. Amphetamine abuse in Sweden: subject demographics, changes in blood concentrations over time, and the types of coingested substances. J Clin Psychopharmacol. 2013. https:\/\/doi.org\/10.1097\/JCP.0b013e3182870310.","journal-title":"J Clin Psychopharmacol"},{"key":"1475_CR28","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.scitotenv.2018.01.274","volume":"627","author":"ASC L\u00f6ve","year":"2018","unstructured":"L\u00f6ve ASC, Baz-Lomba JA, Reid MJ, Kankaanp\u00e4\u00e4 A, Gunnar T, Dam M, et al. Analysis of stimulant drugs in the wastewater of five Nordic capitals. Sci Total Environ. 2018;627:1039\u201347. https:\/\/doi.org\/10.1016\/j.scitotenv.2018.01.274.","journal-title":"Sci Total Environ"},{"key":"1475_CR29","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1080\/13218719.2023.2206870","volume":"31","author":"R Scott","year":"2024","unstructured":"Scott R. Methamphetamine dependence in Australia\u2013why is \u2018ice\u2019 (crystal meth) so addictive? Psychiatry Psychol Law. 2024;31:671\u2013704. https:\/\/doi.org\/10.1080\/13218719.2023.2206870.","journal-title":"Psychiatry Psychol Law"},{"key":"1475_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0252090","volume":"16","author":"K Papamihali","year":"2021","unstructured":"Papamihali K, Collins D, Karamouzian M, Purssell R, Graham B, Buxton J. Crystal methamphetamine use in British Columbia, Canada: a cross-sectional study of people who access harm reduction services. PLoS One. 2021;16:e0252090. https:\/\/doi.org\/10.1371\/journal.pone.0252090.","journal-title":"PLoS One"},{"key":"1475_CR31","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1016\/S0140-6736(24)00367-2","volume":"403","author":"M Naghavi","year":"2024","unstructured":"Naghavi M, Ong KL, Aali A, Ababneh HS, Abate YH, Abbafati C, et al. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403:2100\u201332. https:\/\/doi.org\/10.1016\/S0140-6736(24)00367-2.","journal-title":"Lancet"},{"key":"1475_CR32","doi-asserted-by":"publisher","unstructured":"Leelahanaj T. Comparison of olanzapine with haloperidol in amphetamine-induced psychotic disorder: a double-blind randomized controlled trial [Internet]. Office of Academic Resources, Chulalongkorn University; https:\/\/doi.org\/10.58837\/chula.the.2002.791","DOI":"10.58837\/chula.the.2002.791"},{"key":"1475_CR33","doi-asserted-by":"crossref","unstructured":"Xue X, Song Y, Yu X, Fan Q, Tang J, Chen X. Olanzapine and haloperidol for the treatment of acute symptoms of mental disorders induced by amphetamine-type stimulants: A randomized controlled trial. Medicine. 2018;97.  https:\/\/journals.lww.com\/md-journal\/fulltext\/2018\/02230\/olanzapine_and_haloperidol_for_the_treatment_of.25.aspx","DOI":"10.1097\/MD.0000000000009786"},{"key":"1475_CR34","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1007\/s00213-014-3485-6","volume":"231","author":"V Verachai","year":"2014","unstructured":"Verachai V, Rukngan W, Chawanakrasaesin K, Nilaban S, Suwanmajo S, Thanateerabunjong R, et al. Treatment of methamphetamine-induced psychosis: a double-blind randomized controlled trial comparing haloperidol and quetiapine. Psychopharmacol Springer Sci Bus Media LLC. 2014;231:3099\u2013108. https:\/\/doi.org\/10.1007\/s00213-014-3485-6.","journal-title":"Psychopharmacol Springer Sci Bus Media LLC"},{"key":"1475_CR35","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3109\/00952990.2013.861843","volume":"40","author":"V Farnia","year":"2013","unstructured":"Farnia V, Shakeri J, Tatari F, Juibari TA, Yazdchi K, Bajoghli H, et al. Randomized controlled trial of aripiprazole versus risperidone for the treatment of amphetamine-induced psychosis. Am J Drug Alcohol Abuse Informa UK Ltd. 2013;40:10\u20135. https:\/\/doi.org\/10.3109\/00952990.2013.861843.","journal-title":"Am J Drug Alcohol Abuse Informa UK Ltd"},{"key":"1475_CR36","doi-asserted-by":"publisher","first-page":"108467","DOI":"10.1016\/j.drugalcdep.2020.108467","volume":"219","author":"M Srisurapanont","year":"2021","unstructured":"Srisurapanont M, Likhitsathian S, Suttajit S, Maneeton N, Maneeton B, Oon-arom A, et al. Efficacy and dropout rates of antipsychotic medications for methamphetamine psychosis: A systematic review and network meta-analysis. Drug Alcohol Depend Elsevier BV. 2021;219:108467. https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.108467.","journal-title":"Drug Alcohol Depend Elsevier BV"},{"key":"1475_CR37","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3109\/13651501.2012.667116","volume":"17","author":"AH Sulaiman","year":"2012","unstructured":"Sulaiman AH, Gill JS, Said MA, Zainal NZ, Hussein HM, Guan NC. A randomized, placebo-controlled trial of aripiprazole for the treatment of methamphetamine dependence and associated psychosis. Int J Psychiatry Clin Pract Informa UK Ltd. 2012;17:131\u20138. https:\/\/doi.org\/10.3109\/13651501.2012.667116.","journal-title":"Int J Psychiatry Clin Pract Informa UK Ltd"},{"key":"1475_CR38","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jsat.2015.11.009","volume":"62","author":"G Wang","year":"2016","unstructured":"Wang G, Zhang Y, Zhang S, Chen H, Xu Z, Schottenfeld RS, et al. Aripiprazole and Risperidone for Treatment of Methamphetamine-Associated Psychosis in Chinese Patients. J Subst Abuse Treat Elsevier BV. 2016;62:84\u20138. https:\/\/doi.org\/10.1016\/j.jsat.2015.11.009.","journal-title":"J Subst Abuse Treat Elsevier BV"},{"key":"1475_CR39","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1093\/ijnp\/pyad029","volume":"26","author":"CU Correll","year":"2023","unstructured":"Correll CU, H\u00f8jlund M, Graham C, Todtenkopf MS, McDonnell D, Simmons A. Weight gain and metabolic changes in patients with first-episode psychosis or early-phase schizophrenia treated with Olanzapine: a meta-analysis. International Journal of Neuropsychopharmacology. 2023;26:451\u201364. https:\/\/doi.org\/10.1093\/ijnp\/pyad029.","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"1475_CR40","unstructured":"Moore NA, Leander JD, Benvenga MJ, Gleason SD, Shannon H. Behavioral Pharmacology of Olanzapine: A Novel Antipsychotic Drug. The Journal of Clinical Psychiatry. Physicians Postgraduate Press, Inc. 1997;58:1785. https:\/\/www.psychiatrist.com\/jcp\/behavioral-pharmacology-olanzapine-novel-antipsychotic\/"},{"key":"1475_CR41","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.2147\/pgpm.s391401","volume":"16","author":"P Kolli","year":"2023","unstructured":"Kolli P, Kelley G, Rosales M, Faden J, Serdenes R. Olanzapine pharmacokinetics: a clinical review of current insights and remaining questions. Pharmacogenomics and Personalized Medicine. 2023;16:1097\u2013108. https:\/\/doi.org\/10.2147\/pgpm.s391401.","journal-title":"Pharmacogenomics and Personalized Medicine"},{"key":"1475_CR42","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/bf02244923","volume":"112","author":"CF Saller","year":"1993","unstructured":"Saller CF, Salama AI. Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacol Springer Sci Bus Media LLC. 1993;112:285\u201392. https:\/\/doi.org\/10.1007\/bf02244923.","journal-title":"Psychopharmacol Springer Sci Bus Media LLC"},{"key":"1475_CR43","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.2174\/1570159x15666170630163616","volume":"16","author":"S Siafis","year":"2018","unstructured":"Siafis S, Tzachanis D, Samara M, Papazisis G. Antipsychotic Drugs: From Receptor-binding Profiles to Metabolic Side Effects. Current Neuropharmacology. Bentham Sci Publishers Ltd. 2018;16:1210\u201323. https:\/\/doi.org\/10.2174\/1570159x15666170630163616.","journal-title":"Bentham Sci Publishers Ltd"},{"key":"1475_CR44","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1176\/appi.focus.20200051","volume":"19","author":"HY Meltzer","year":"2021","unstructured":"Meltzer HY, Gadaleta E. Contrasting Typical and Atypical Antipsychotic Drugs. Focus. Am Psychiatric Association Publishing. 2021;19:3\u201313. https:\/\/doi.org\/10.1176\/appi.focus.20200051.","journal-title":"Am Psychiatric Association Publishing"},{"key":"1475_CR45","doi-asserted-by":"publisher","DOI":"10.1017\/cbo9780511919237","volume-title":"Antipsychotics and their Side Effects","author":"DM Gardner","year":"2010","unstructured":"Gardner DM, Teehan MD, Baldessarini R. Antipsychotics and their Side Effects. Cambridge University Press; 2010. https:\/\/doi.org\/10.1017\/cbo9780511919237."},{"key":"1475_CR46","unstructured":"Highlights of Prescribing Information: Zyprexa (Olanzapine) Tablets, Zyprexa Zydis (Olanzapine) Orally Disintegrating Tablets, Zyprexa Intramuscular (Olanzapine) for Injection [Internet]. Eli Lilly. 2008. https:\/\/pi.lilly.com\/us\/zyprexa-pi.pdf"},{"key":"1475_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/656370","volume":"2014","author":"N Divac","year":"2014","unstructured":"Divac N, Prostran M, Jakovcevski I, Cerovac N. Second-generation antipsychotics and extrapyramidal adverse effects. BioMed Res Int. 2014;2014:1\u20136. https:\/\/doi.org\/10.1155\/2014\/656370.","journal-title":"BioMed Res Int"},{"key":"1475_CR48","first-page":"306","volume":"42","author":"S Hosseini","year":"2017","unstructured":"Hosseini S, Elyasi F. Olanzapine-induced Neuroleptic Malignant Syndrome. Iran J Med Sci. 2017;42:306\u20139.","journal-title":"Iran J Med Sci"},{"key":"1475_CR49","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/s2215-0366(25)00025-2","volume":"12","author":"N Nomura","year":"2025","unstructured":"Nomura N, Siafis S, Schneider-Thoma J, Brandt L, Park J, Efthimiou O, et al. The trajectory of sedative adverse events caused by antipsychotics: a meta-analysis of individual participant data from randomised, placebo-controlled, clinical trials in acute phase Schizophrenia. Lancet Psychiatry. 2025;12:266\u201375. https:\/\/doi.org\/10.1016\/s2215-0366(25)00025-2.","journal-title":"Lancet Psychiatry"},{"key":"1475_CR50","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2165\/00003088-199937030-00001","volume":"37","author":"JT Callaghan","year":"1999","unstructured":"Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. Olanzapine. Clinical Pharmacokinetics. 1999;37:177\u201393. https:\/\/doi.org\/10.2165\/00003088-199937030-00001.","journal-title":"Clinical Pharmacokinetics"},{"key":"1475_CR51","doi-asserted-by":"publisher","first-page":"21","DOI":"10.17161\/kjm.vol18.22846","volume":"18","author":"K Surineni","year":"2025","unstructured":"Surineni K, Smith A, Glein R, Schrader N. A case of Olanzapine resistance from heavy smoking and clinical considerations. Kans J Med. 2025;18:21\u20132. https:\/\/doi.org\/10.17161\/kjm.vol18.22846.","journal-title":"Kans J Med"},{"key":"1475_CR52","doi-asserted-by":"publisher","first-page":"280","DOI":"10.9740\/mhc.2024.10.280","volume":"14","author":"J Laub","year":"2024","unstructured":"Laub J, Treu CN, Takamura K, Mendoza C. A retrospective review of intramuscular Olanzapine and parenteral benzodiazepine coadministration in the emergency department. Ment Health Clin. 2024;14:280\u20135. https:\/\/doi.org\/10.9740\/mhc.2024.10.280.","journal-title":"Ment Health Clin"},{"key":"1475_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/570410","volume":"2015","author":"S Duong","year":"2015","unstructured":"Duong S, Yeung K-T, Chang F. Intramuscular Olanzapine in the management of behavioral and psychological symptoms in hospitalized older adults: a retrospective descriptive study. J Aging Res. 2015;2015:1\u20136. https:\/\/doi.org\/10.1155\/2015\/570410.","journal-title":"J Aging Res"},{"key":"1475_CR54","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.59.5.441","volume":"59","author":"A Breier","year":"2002","unstructured":"Breier A, Meehan K, Birkett M, David S, Ferchland I, Sutton V, et al. A double-blind, placebo-controlled dose-response comparison of intramuscular Olanzapine and Haloperidol in the treatment of acute agitation in Schizophrenia. Arch Gen Psychiatry. 2002;59:441. https:\/\/doi.org\/10.1001\/archpsyc.59.5.441.","journal-title":"Arch Gen Psychiatry"},{"key":"1475_CR55","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1080\/13651500701749859","volume":"12","author":"A Montoya","year":"2008","unstructured":"Montoya A, San L, Manuel Olivares J, P\u00e9rez-Sola V, Casillas M, L\u00f3pez-Carrero C, et al. Clinical characteristics of agitated psychotic patients treated with an oral antipsychotics attended in the emergency room setting: NATURA study. Int J Psychiatry Clin Pract. 2008;12:127\u201333. https:\/\/doi.org\/10.1080\/13651500701749859.","journal-title":"Int J Psychiatry Clin Pract"},{"key":"1475_CR56","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000035663","volume":"103","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, Zhang X, Xu L. Comparative efficacy and safety of olanzapine and risperidone in the treatment of psychiatric and behavioral symptoms of Alzheimer\u2019s disease: systematic review and meta-analysis. Medicine. 2024;103:e35663. https:\/\/doi.org\/10.1097\/md.0000000000035663.","journal-title":"Medicine"},{"key":"1475_CR57","doi-asserted-by":"publisher","first-page":"4178","DOI":"10.1200\/jco.23.01280","volume":"41","author":"EJ Roeland","year":"2023","unstructured":"Roeland EJ, Bohlke K, Baracos VE, Smith TJ, Loprinzi CL, Bruera E, et al. Cancer cachexia: ASCO guideline rapid recommendation update. J Clin Oncol. 2023;41:4178\u20139. https:\/\/doi.org\/10.1200\/jco.23.01280.","journal-title":"J Clin Oncol"},{"key":"1475_CR58","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.jpsychires.2021.11.023","volume":"149","author":"J Berge","year":"2022","unstructured":"Berge J, Abri P, Andell P, Movahed P, Ragazan DC. Associations between off-label low-dose olanzapine or quetiapine and cardiometabolic mortality. J Psychiatr Res. 2022;149:352\u20138. https:\/\/doi.org\/10.1016\/j.jpsychires.2021.11.023.","journal-title":"J Psychiatr Res"},{"issue":"1","key":"1475_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/s40337-023-00862-4","volume":"11","author":"B Frank","year":"2023","unstructured":"Frank B, Arnold S, Jaite C, Correll CU. Antipsychotic effects on anthropometric outcomes in anorexia nervosa: a retrospective chart review of hospitalized children and adolescents. Journal of Eating Disorders. 2023;11. https:\/\/doi.org\/10.1186\/s40337-023-00862-4.","journal-title":"Journal of Eating Disorders"},{"key":"1475_CR60","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1176\/appi.ajp.2018.18101125","volume":"176","author":"E Attia","year":"2019","unstructured":"Attia E, Steinglass JE, Walsh BT, Wang Y, Wu P, Schreyer C, et al. Olanzapine versus placebo in adult outpatients with anorexia nervosa: a randomized clinical trial. AJP. 2019;176:449\u201356. https:\/\/doi.org\/10.1176\/appi.ajp.2018.18101125.","journal-title":"AJP"},{"key":"1475_CR61","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/00004850-200207000-00004","volume":"17","author":"N Lindberg","year":"2002","unstructured":"Lindberg N, Virkkunen M, Tani P, Appelberg B, Virkkala J, Rim??n R, et al. Effect of a single-dose of olanzapine on sleep in healthy females and males. Int Clin Psychopharmacol. 2002;17:177\u201384. https:\/\/doi.org\/10.1097\/00004850-200207000-00004.","journal-title":"Int Clin Psychopharmacol"},{"issue":"2","key":"1475_CR62","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.119","volume":"3","author":"A Nahmias","year":"2020","unstructured":"Nahmias A, Stahel P, Dash S. Assessment of lipid response to acute olanzapine administration in healthy adults. Endocrinology, Diabetes & Metabolism. 2020;3. https:\/\/doi.org\/10.1002\/edm2.119.","journal-title":"Endocrinology, Diabetes & Metabolism"},{"key":"1475_CR63","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1097\/jcp.0b013e31829e8333","volume":"33","author":"MK Hahn","year":"2013","unstructured":"Hahn MK, Wolever TMS, Arenovich T, Teo C, Giacca A, Powell V, et al. Acute effects of single-dose olanzapine on metabolic, endocrine, and inflammatory markers in healthy controls. J Clin Psychopharmacol. 2013;33:740\u20136. https:\/\/doi.org\/10.1097\/jcp.0b013e31829e8333.","journal-title":"J Clin Psychopharmacol"},{"key":"1475_CR64","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.55.5.443","volume":"55","author":"MS Keshavan","year":"1998","unstructured":"Keshavan MS, Reynolds CF, Miewald JM, Montrose DM, Sweeney JA, Vasko RC, et al. Delta sleep deficits in schizophrenia. Arch Gen Psychiatry. 1998;55:443. https:\/\/doi.org\/10.1001\/archpsyc.55.5.443.","journal-title":"Arch Gen Psychiatry"},{"key":"1475_CR65","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1093\/cercor\/bhn155","volume":"19","author":"M Nishida","year":"2008","unstructured":"Nishida M, Pearsall J, Buckner RL, Walker MP. REM sleep, prefrontal theta, and the consolidation of human emotional memory. Cerebral Cortex. 2008;19:1158\u201366. https:\/\/doi.org\/10.1093\/cercor\/bhn155.","journal-title":"Cerebral Cortex"},{"key":"1475_CR66","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s00213-006-0690-y","volume":"191","author":"B Abler","year":"2007","unstructured":"Abler B, Erk S, Walter H. Human reward system activation is modulated by a single dose of olanzapine in healthy subjects in an event-related, double-blind, placebo-controlled fMRI study. Psychopharmacology Berl. 2007;191:823\u201333. https:\/\/doi.org\/10.1007\/s00213-006-0690-y.","journal-title":"Psychopharmacology Berl"},{"key":"1475_CR67","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1192\/apt.bp.109.007310","volume":"17","author":"JJ Schleifer","year":"2011","unstructured":"Schleifer JJ. Management of acute agitation in psychosis: an evidence-based approach in the USA. Adv Psychiatr Treat. 2011;17:91\u2013100. https:\/\/doi.org\/10.1192\/apt.bp.109.007310.","journal-title":"Adv Psychiatr Treat"},{"key":"1475_CR68","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1097\/jcp.0b013e3182670648","volume":"32","author":"ME McLarnon","year":"2012","unstructured":"McLarnon ME, Fulton HG, MacIsaac C, Barrett SP. Characteristics of Quetiapine misuse among clients of a community-based methadone maintenance program. J Clin Psychopharmacol. 2012;32:721\u20133. https:\/\/doi.org\/10.1097\/jcp.0b013e3182670648.","journal-title":"J Clin Psychopharmacol"},{"key":"1475_CR69","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jsat.2014.07.006","volume":"48","author":"T Malekshahi","year":"2015","unstructured":"Malekshahi T, Tioleco N, Ahmed N, Campbell ANC, Haller D. Misuse of atypical antipsychotics in conjunction with alcohol and other drugs of abuse. J Subst Abuse Treat. 2015;48:8\u201312. https:\/\/doi.org\/10.1016\/j.jsat.2014.07.006.","journal-title":"J Subst Abuse Treat"},{"key":"1475_CR70","first-page":"6","volume":"7","author":"RA Sansone","year":"2010","unstructured":"Sansone RA, Sansone LA. Is seroquel developing an illicit reputation for misuse\/abuse? Psychiatry (Edgmont). 2010;7:6\u201313.","journal-title":"Psychiatry (Edgmont)"},{"key":"1475_CR71","doi-asserted-by":"publisher","unstructured":"Diana M. The Dopamine Hypothesis of Drug Addiction and Its Potential Therapeutic Value. Frontiers in Psychiatry [Internet]. Front Media SA. 2011;2. https:\/\/doi.org\/10.3389\/fpsyt.2011.00064.","DOI":"10.3389\/fpsyt.2011.00064"},{"key":"1475_CR72","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/j.1744-6163.2008.00175.x","volume":"44","author":"NL Keltner","year":"2008","unstructured":"Keltner NL, Vance DE. Biological perspectives incarcerated care and Quetiapine abuse. Perspect Psychiatr Care. 2008;44:202\u20136. https:\/\/doi.org\/10.1111\/j.1744-6163.2008.00175.x.","journal-title":"Perspect Psychiatr Care"},{"key":"1475_CR73","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1176\/ajp.2007.164.1.173a","volume":"164","author":"BM Waters","year":"2007","unstructured":"Waters BM, Joshi KG. Intravenous Quetiapine-cocaine use (\u201cQ-Ball\u201d). Am J Psychiatry. 2007;164:173\u20134. https:\/\/doi.org\/10.1176\/ajp.2007.164.1.173a.","journal-title":"Am J Psychiatry"},{"key":"1475_CR74","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.neubiorev.2009.11.003","volume":"34","author":"BA Fischer","year":"2010","unstructured":"Fischer BA, Boggs DL. The role of antihistaminic effects in the misuse of Quetiapine: a case report and review of the literature. Neurosci Biobehav Rev. 2010;34:555\u20138. https:\/\/doi.org\/10.1016\/j.neubiorev.2009.11.003.","journal-title":"Neurosci Biobehav Rev"},{"key":"1475_CR75","doi-asserted-by":"publisher","DOI":"10.1177\/1178221819844205","author":"KE Evoy","year":"2019","unstructured":"Evoy KE, Teng C, Encarnacion VG, Frescas B, Hakim J, Saklad S, et al. Comparison of quetiapine abuse and misuse reports to the FDA Adverse Event Reporting System with other second-generation antipsychotics. Subst Abuse Res Treat. 2019. https:\/\/doi.org\/10.1177\/1178221819844205.","journal-title":"Subst Abuse Res Treat"},{"key":"1475_CR76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/19585969.2025.2449833","volume":"27","author":"H Verdoux","year":"2025","unstructured":"Verdoux H. Antipsychotic off-label use in the 21st century: an enduring public health concern. Dialogues Clin Neurosci. 2025;27:1\u201312. https:\/\/doi.org\/10.1080\/19585969.2025.2449833.","journal-title":"Dialogues Clin Neurosci"},{"key":"1475_CR77","unstructured":"Kane S. The Top 200 of 2023. 2023. https:\/\/clincalc.com\/DrugStats\/"},{"key":"1475_CR78","doi-asserted-by":"crossref","unstructured":"Nielsen S, Bruno R, Schenk S. Non-medical and illicit use of psychoactive drugs. 2017.","DOI":"10.1007\/978-3-319-60016-1"},{"key":"1475_CR79","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.pnpbp.2010.07.031","volume":"34","author":"C-H Lai","year":"2010","unstructured":"Lai C-H. Olanzapine abuse was relieved after switching to aripiprazole in a patient with psychotic depression. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34:1363\u20134. https:\/\/doi.org\/10.1016\/j.pnpbp.2010.07.031.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"1475_CR80","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/08897077.2012.709222","volume":"34","author":"NA Kumsar","year":"2013","unstructured":"Kumsar NA, Erol A. Olanzapine abuse. Subst Abus. 2013;34:73\u20134. https:\/\/doi.org\/10.1080\/08897077.2012.709222.","journal-title":"Subst Abus"},{"key":"1475_CR81","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1080\/02791072.2007.10400617","volume":"39","author":"RR Reeves","year":"2007","unstructured":"Reeves RR. Abuse of olanzapine by substance abusers. J Psychoactive Drugs. 2007;39:297\u20139. https:\/\/doi.org\/10.1080\/02791072.2007.10400617.","journal-title":"J Psychoactive Drugs"},{"key":"1475_CR82","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1002\/hup.2431","volume":"30","author":"G Valeriani","year":"2015","unstructured":"Valeriani G, Corazza O, Bersani FS, Melcore C, Metastasio A, Bersani G, et al. Olanzapine as the ideal \u201ctrip terminator\u201d? Analysis of online reports relating to antipsychotics\u2019 use and misuse following occurrence of novel psychoactive substance-related psychotic symptoms. Hum Psychopharmacol. 2015;30:249\u201354. https:\/\/doi.org\/10.1002\/hup.2431.","journal-title":"Hum Psychopharmacol"},{"key":"1475_CR83","doi-asserted-by":"publisher","first-page":"386","DOI":"10.3109\/09638237.2012.682265","volume":"21","author":"Z Davey","year":"2012","unstructured":"Davey Z, Schifano F, Corazza O, Deluca P. e-Psychonauts: conducting research in online drug forum communities. J Ment Health. 2012;21:386\u201394. https:\/\/doi.org\/10.3109\/09638237.2012.682265.","journal-title":"J Ment Health"},{"key":"1475_CR84","doi-asserted-by":"publisher","first-page":"f174","DOI":"10.1136\/bmj.f174","volume":"346","author":"AY Walley","year":"2013","unstructured":"Walley AY, Xuan Z, Hackman HH, Quinn E, Doe-Simkins M, Sorensen-Alawad A, et al. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ. 2013;346:f174\u2013f174. https:\/\/doi.org\/10.1136\/bmj.f174.","journal-title":"BMJ"},{"key":"1475_CR85","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1111\/add.14510","volume":"114","author":"J Neale","year":"2018","unstructured":"Neale J, Brown C, Campbell ANC, Jones JD, Metz VE, Strang J, et al. How competent are people who use opioids at responding to overdoses? Qualitative analyses of actions and decisions taken during overdose emergencies. Addiction. 2018;114:708\u201318. https:\/\/doi.org\/10.1111\/add.14510.","journal-title":"Addiction"},{"key":"1475_CR86","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-019-0352-0","author":"BL Hanson","year":"2020","unstructured":"Hanson BL, Porter RR, Z\u00f6ld AL, Terhorst-Miller H. Preventing opioid overdose with peer-administered naloxone: findings from a rural state. Harm Reduct J. 2020. https:\/\/doi.org\/10.1186\/s12954-019-0352-0.","journal-title":"Harm Reduct J"},{"key":"1475_CR87","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.drugpo.2008.02.004","volume":"20","author":"SG Sherman","year":"2009","unstructured":"Sherman SG, Gann DS, Tobin KE, Latkin CA, Welsh C, Bielenson P. \u201cThe life they save may be mine\u201d: diffusion of overdose prevention information from a city sponsored programme. Int J Drug Policy. 2009;20:137\u201342. https:\/\/doi.org\/10.1016\/j.drugpo.2008.02.004.","journal-title":"Int J Drug Policy"},{"key":"1475_CR88","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1080\/08897077.2016.1238431","volume":"37","author":"CS Davis","year":"2016","unstructured":"Davis CS, Burris S, Beletsky L, Binswanger I. Co-prescribing naloxone does not increase liability risk. Subst Abus. 2016;37:498\u2013500. https:\/\/doi.org\/10.1080\/08897077.2016.1238431.","journal-title":"Subst Abus"},{"key":"1475_CR89","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.addbeh.2018.03.014","volume":"86","author":"C McClellan","year":"2018","unstructured":"McClellan C, Lambdin BH, Ali MM, Mutter R, Davis CS, Wheeler E, et al. Opioid-overdose laws association with opioid use and overdose mortality. Addict Behav. 2018;86:90\u20135. https:\/\/doi.org\/10.1016\/j.addbeh.2018.03.014.","journal-title":"Addict Behav"},{"key":"1475_CR90","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-14-297","author":"M Doe-Simkins","year":"2014","unstructured":"Doe-Simkins M, Quinn E, Xuan Z, Sorensen-Alawad A, Hackman H, Ozonoff A, et al. Overdose rescues by trained and untrained participants and change in opioid use among substance-using participants in overdose education and naloxone distribution programs: a retrospective cohort study. BMC Public Health. 2014. https:\/\/doi.org\/10.1186\/1471-2458-14-297.","journal-title":"BMC Public Health"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-026-01475-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-026-01475-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-026-01475-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T04:08:09Z","timestamp":1781150889000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12954-026-01475-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":90,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1475"],"URL":"https:\/\/doi.org\/10.1186\/s12954-026-01475-1","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"6 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"103"}}